<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113141</article-id><article-id pub-id-type="publisher-id">ACM-40890</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_49441772.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  IL-23/IL-17炎症通路在中轴型脊柱关节炎发病机制及治疗中的研究进展
  Research Progress of IL-23/IL-17 Axis in the Pathogenesis and Treatment of Axial Spondyloarthritis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>扬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>琦</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>上海中医药大学，上海</addr-line></aff><aff id="aff3"><addr-line>上海中医药大学附属光华医院，关节内科，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>981</fpage><lpage>989</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    IL-23/IL-17炎症通路在中轴型脊柱关节炎(Axial Spondyloarthritis, axSpA)的发病机制中逐渐成为热点研究方向。随着基因技术的发展，该炎症轴与SpA之间关联也愈加清晰，临床中针对axSpA中IL-17的抑制也取得了较好的治疗结果，但针对IL-23抑制的治疗结果不理想，对于IL-23/IL-17炎症通路在axSpA发病中的作用仍有较多的矛盾与未知。本文主要针对IL-23/IL-17炎症通路在axSpA中的发病机制及临床治疗的研究进展进行了综述。
    The IL-23/IL-17 Axis has gradually received more attention in the pathogenesis of Axial Spondyloarthritis (axSpA). With the development of gene technology, the relationship between the axis and SpA has become more and more clear. Clinically, the inhibition of IL-17 in axSpA has also achieved good treatment results, but the results of treatment for IL-23 inhibition are not satisfactory. There are still many contradictions and unknowns about the role of IL-23/IL-17 Axis in the pathogenesis of axSpA. This article mainly reviews the research progress of IL-23/IL-17 Axis in axSpA and clinical treatment. 
  
 
</p></abstract><kwd-group><kwd>中轴型脊柱关节炎，强直性脊柱炎，IL-23/IL-17炎症通路，机制，临床进展, Axial Spondyloarthritis</kwd><kwd> Ankylosing Spondylitis</kwd><kwd> IL-23/IL-17 Axis</kwd><kwd> Mechanism</kwd><kwd> Clinical Progress</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>IL-23/IL-17炎症通路在中轴型脊柱关节炎(Axial Spondyloarthritis, axSpA)的发病机制中逐渐成为热点研究方向。随着基因技术的发展，该炎症轴与SpA之间关联也愈加清晰，临床中针对axSpA中IL-17的抑制也取得了较好的治疗结果，但针对IL-23抑制的治疗结果不理想，对于IL-23/IL-17炎症通路在axSpA发病中的作用仍有较多的矛盾与未知。本文主要针对IL-23/IL-17炎症通路在axSpA中的发病机制及临床治疗的研究进展进行了综述。</p></sec><sec id="s2"><title>关键词</title><p>中轴型脊柱关节炎，强直性脊柱炎，IL-23/IL-17炎症通路，机制，临床进展</p></sec><sec id="s3"><title>Research Progress of IL-23/IL-17 Axis in the Pathogenesis and Treatment of Axial Spondyloarthritis<sup> </sup></title><p>Yang Liu<sup>1</sup>, Qi Zhu<sup>2*</sup></p><p><sup>1</sup>Shanghai University of Traditional Chinese Medicine, Shanghai</p><p><sup>2</sup>Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional and Western Medicine, Shanghai</p><p><img src="//html.hanspub.org/file/24-1572002x4_hanspub.png" /></p><p>Received: Feb. 11<sup>th</sup>, 2021; accepted: Mar. 1<sup>st</sup>, 2021; published: Mar. 12<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/24-1572002x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The IL-23/IL-17 Axis has gradually received more attention in the pathogenesis of Axial Spondyloarthritis (axSpA). With the development of gene technology, the relationship between the axis and SpA has become more and more clear. Clinically, the inhibition of IL-17 in axSpA has also achieved good treatment results, but the results of treatment for IL-23 inhibition are not satisfactory. There are still many contradictions and unknowns about the role of IL-23/IL-17 Axis in the pathogenesis of axSpA. This article mainly reviews the research progress of IL-23/IL-17 Axis in axSpA and clinical treatment.</p><p>Keywords:Axial Spondyloarthritis, Ankylosing Spondylitis, IL-23/IL-17 Axis, Mechanism, Clinical Progress</p><disp-formula id="hanspub.40890-formula26"><graphic xlink:href="//html.hanspub.org/file/24-1572002x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/24-1572002x8_hanspub.png" /> <img src="//html.hanspub.org/file/24-1572002x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>脊柱关节炎(Spondyloarthritis, SpA)是一组慢性炎症性疾病，主要表现为中轴脊柱病变或伴有外周关节炎，以肌腱附着点炎及进行性骨强直为特点，或伴有关节外表现，如银屑病、葡萄膜炎、肠炎等。这一类疾病包括：以强直性脊柱炎(Ankylosing Spondylitis, AS)为代表的中轴型脊柱关节炎(axSpA)以及以外周关节或关节外表现为主的反应性关节炎(Reactive Arthritis, ReA)、银屑病关节炎(Psoriatic Arthritis, PsA)、炎症性肠病性关节炎(Arthropathy of Inflammatory Bowel Disease, IBD)、未分化脊柱关节炎(undifferentiated Spondyloarthritis, uSpA) [<xref ref-type="bibr" rid="hanspub.40890-ref1">1</xref>]。白介素-23 (IL-23)是一种异源二聚性细胞因子，由与IL-12共有的IL-12B (IL-12p40)亚基和IL-23A (IL-23p19)亚基组成，可以促进Th17细胞、γ/δT细胞、固有淋巴细胞(ILCs)等免疫细胞分泌白介素-17 (IL-17)、白介素-22 (IL-22)等细胞因子。IL-23/IL-17炎症通路在许多免疫疾病中都起到了关键性的作用，通过基因关联分析发现IL-23/IL-17炎症通路与SpA发病存在相关性，临床上IL-17抑制剂对于SpA治疗也取得了满意的疗效，但IL-23抑制剂对于axSpA治疗失败也表明IL-23/IL-17在axSpA中存在疾病的特异性，近年来也发现固有免疫细胞在其中可能有着关键的作用。本文主要讨论IL-23/IL-17炎症通路在axSpA中的最新的研究进展。</p></sec><sec id="s6"><title>2. 基因相关研究</title><p>在基因相关研究中，最早通过整合基因组学方法的研究中证实了AS的风险等位基因与IL-17通路相关基因之间存在重叠 [<xref ref-type="bibr" rid="hanspub.40890-ref2">2</xref>]。基因关联研究(GWAS)的结果表明Th17信号传导途径以及IL23R多态性在AS发病机理中起着关键作用 [<xref ref-type="bibr" rid="hanspub.40890-ref3">3</xref>]。除了基因本身的多态性外，编码IL-23的IL-12p40亚基的IL12B位点附近的变异也与AS有关 [<xref ref-type="bibr" rid="hanspub.40890-ref4">4</xref>]。同样有研究发现了多个axSpA相关的非MHC位点与IL-23/IL-17炎症通路中的基因(RUNX3、IL23R、IL6R、IL1R2、IL12B、TYK2)相关 [<xref ref-type="bibr" rid="hanspub.40890-ref5">5</xref>]。位于TYK2位点上的变异通过影响TYK2剪接作用影响IL-23/IL-17炎症通路参与AS的发病 [<xref ref-type="bibr" rid="hanspub.40890-ref6">6</xref>]。这些研究表明IL-23/IL-17炎症通路参与axSpA的发病。</p></sec><sec id="s7"><title>3. 临床药物试验</title><p>在过去几年里，在以IL-23/IL-17炎症通路为靶点治疗axSpA的临床试验中，IL-17抑制剂取得了良好的临床疗效。目前，2019的ACR/SAA指南建议对于初次对TNF抑制剂无反应的AS患者，推荐使用Secukinumab或Ixekizumab这两种IL-17抑制剂 [<xref ref-type="bibr" rid="hanspub.40890-ref7">7</xref>]。</p><p>Secukinumab是一种重组人IgG1 kappa单克隆抗体，可与IL-17A结合，从而减少对滑膜、肌腱附着点和表达IL-17受体的细胞(如角质细胞)的促炎作用。在为期三年的III期双盲安慰剂对照试验MEASURE1和MEASURE2中Secukinumab治疗组在ASAS20、ASAS40应答率均优于对照组，未发现较高的不良事件率和意外的安全性事件 [<xref ref-type="bibr" rid="hanspub.40890-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40890-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.40890-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40890-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40890-ref12">12</xref>]。</p><p>另一种IL-17单抗Ixekizumab是一种重组、高亲和力、人源化的免疫球蛋白G4 (IgG4) kappa单克隆抗体，可选择性地结合和中和IL-17A，对同二聚体IL-17A/A和异二聚体IL-17A/F具有很高的结合亲和力，但对IL-17家族的其他成员没有很高的结合亲和力。对于Ixekizumab近年共有三项关于AS或asSpA的药物临床试验。其中III期双盲安慰剂对照试验(COAST-V)主要招募了未使用生物制剂(bDMARD)治疗的AS和axSpA患者，另一项III期双盲安慰剂对照试(COAST-W)主要招募了曾经使用过TNF抑制剂的asSpA患者(对TNF抑制剂无反应或不耐受)，两项临床试验结果都显示Ixekizumab对AS的良好疗效，使用Ixekizumab治疗的AS患者在多个结果中比安慰剂治疗的患者有更大的改善，安全性上与Ixekizumab之前的药物临床试验一致。近期报道了第三项Ixekizumab的双盲随机对照试验(COAST-X)结果，主要招募非影像学诊断的axSpA患者，在16周和52周的axSpA患者的体征、症状和客观炎性反应方面Ixekizumab治疗组优于安慰剂，不良事件的报告与以前的Ixekizumab临床试验研究相似 [<xref ref-type="bibr" rid="hanspub.40890-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40890-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40890-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.40890-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40890-ref17">17</xref>]。</p><p>另外最新的一项针对IL-17A与IL-17F双重中和抗体Bimekizumab治疗AS的临床试验已经进入到II期，Bimekizumab是一种可选择性中和IL-17A和IL-17F的单克隆抗体，在治疗银屑病性关节炎(PsA)已经取得了较好的疗效。试验结果显示12周与48周Bimekizumab治疗组的ASAS40应答率均高于对照组，安全性方面与之前的Bimekizumab研究一致，并且与IL-17A抑制剂相当 [<xref ref-type="bibr" rid="hanspub.40890-ref18">18</xref>]。</p><p>尽管IL-23同样发现了与AS之间的关联，但几项临床试验的结果却是失望的。在两项IL-23单抗的随机对照试验中，其中一项使用Ustekinumab (针对IL-12与IL-23共同的p40链)，另一项使用Risankizumab (针对IL-23的p19链)，IL-23抑制剂对AS的影响均没有超过安慰剂的效果。在同两种IL-23抑制剂治疗银屑病与克罗恩病的临床试验对比后，排除了药物剂量不足的可能性。其中Ustekinumab的三项临床试验中，第一项因主要及次要终点均未达到因此被终止，导致剩余两项试验在登记之前就提前终止了。第一项试验数据显示Ustekinumab剂量组与安慰剂组在关键疗效终点上均未显示有临床意义的改善 [<xref ref-type="bibr" rid="hanspub.40890-ref19">19</xref>]。在Risankizumab试验中，对于Risankizumab治疗24周ASAS20未达标的患者，使用120 mg Risankizumab继续治疗至40周后仍未取得疾病活动的改善 [<xref ref-type="bibr" rid="hanspub.40890-ref20">20</xref>]。另外还有一项针对axSpA患者的IL-23抑制剂Tildrakizumab (针对p19链)的临床试验(NCT02980705)同样也被终止了。</p></sec><sec id="s8"><title>4. IL-23/IL-17相关固有免疫细胞</title><p>以往的研究结果并不能解释临床药物实验中IL-17、IL-23抑制剂不同的结果，但有研究者通过HLA-B27/hβ2m转基因大鼠诱导实验性脊柱炎，分别在发病前预防性使用IL-23抑制剂及发病后使用IL-23抑制剂，发现IL-23抑制剂可以预防脊柱炎的发生，但对已发展成脊柱炎的大鼠则不起治疗作用，相反IL-17抑制剂比其更有效，因此可以推测细胞因子的作用可能因疾病的发展阶段不同而不同 [<xref ref-type="bibr" rid="hanspub.40890-ref21">21</xref>]。在另一项HLA-B27/hβ2m转基因大鼠中使用IL-17A抑制剂阻断后，其预防性和治疗性抑制均可以减轻大鼠中轴和外周关节的炎症，防止新骨形成，也可以减少骨质流失，体外实验则发现IL-17A可以显着增强成骨细胞分化 [<xref ref-type="bibr" rid="hanspub.40890-ref22">22</xref>]。这两项实验结果与临床药物试验结果相似，IL-23似乎在疾病最初阶段发挥作用，但在已形成的疾病中作用则下降，而IL-17在疾病的整个过程中始终起着关键作用，而且能导致骨质流失并促进新骨形成。有学者认为这可能是IL-23/IL-17炎症通路解耦合导致的结果 [<xref ref-type="bibr" rid="hanspub.40890-ref23">23</xref>]，但Sherlock等通过IL-23刺激小鼠肌腱端常驻RORγt<sup>+</sup>CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>−</sup>T细胞，可以诱导产生IL-17A、IL-22和IL-17F细胞因子，最终发展成骶髂炎、肌腱端炎和脊柱炎等，进一步的研究发现小鼠的发病不依赖于Th17细胞 [<xref ref-type="bibr" rid="hanspub.40890-ref24">24</xref>]。同样从最近在axSpA患者中或健康人体内发现许多非IL-23依赖的IL-17分泌细胞以及受到其中大多数为固有免疫细胞，因此这些固有免疫细胞可能是解释这一现象的关键。</p><sec id="s8_1"><title>4.1. 固有淋巴细胞(ILCs)</title><p>3型ILC (ILC3)以转录因子RORγt为特征，主要分泌Th17相关的细胞因子，如IL-17和IL-22，主要存在于肠道、肌腱端和骨髓中，他们可以表达IL-23受体，在IL-23的刺激下可导致IL-17水平的上调。Francesco Ciccia等 [<xref ref-type="bibr" rid="hanspub.40890-ref25">25</xref>] 在AS患者肠道中发现分泌IL-17及IL-22的ILC3细胞，并在外周血、关节滑液和骨髓中扩增，产生高水平的IL-17和IL-22，以及表达α4β7整合素，α4β7的特异性受体是黏膜地址素细胞黏附分子(MAdCAM-1)，同样在AS患者的肠道以及骨髓的ILC3中显著上调，对肠道和骨髓中的ILC3切片染色后确定这些ILC3起源于肠道，表明AS中存在肠-关节/脊柱轴，其中ILC3在肠道中活跃分化，其发育与淋巴组织诱导(LTi)细胞相关，发育过程需要IL-7信号刺激 [<xref ref-type="bibr" rid="hanspub.40890-ref26">26</xref>]，与健康对照组相比，AS患者高表达IL-7相关mRNA，对IL-7表达组织及分布位置分析表明这些IL-7由肠道潘氏细胞分泌，随后活化的ILC3迁移到肠外关节或骨髓，产生IL-17和IL-22，这可能是引起炎症的原因。但在最近的另一项研究从SpA患者的关节滑膜中分离出ILC3，在体外使用IL-23/IL-1β刺激后仅产生IL-22和集落刺激因子(GM-CSF)，并不产生IL-17A [<xref ref-type="bibr" rid="hanspub.40890-ref27">27</xref>]。一种可能是ILC3并非IL-17A的主要来源，另一种可能是ILC3需要受其他的刺激下产生IL-17A。这个结果与另一项研究结果相似，在SpA患者外周血中发现了IL-17A<sup>+</sup>GM-CSF<sup>+</sup>Th17细胞，并在滑膜中产生GM-CSF；在炎症关节中发现了仅产生GM-CSF为主的ILC3 [<xref ref-type="bibr" rid="hanspub.40890-ref28">28</xref>]，GM-CSF在AS中可以促进单核细胞反应，产生TNF及IL-23炎症因子 [<xref ref-type="bibr" rid="hanspub.40890-ref29">29</xref>]。这两项研究结果都表明ILC3可能并不是IL-17A最主要的来源。最近也有研究者发现了AS患者中的ILC3与单核细胞之间的作用，在AS患者肠道中发现了分泌IL-23的CX3CR1<sup>+</sup>CD59<sup>+</sup>单核细胞的扩增，与外周血的ILC3体外共培养后发现这类单核细胞可以促进ILC3扩增并分泌IL-22，同时还发现该类单核细胞表达CCR9归巢受体，因此推测该单核细胞可能来源于肠道，并在外周促进ILC3的功能表达，表明这可能是一种潜在的肠–关节/脊柱轴 [<xref ref-type="bibr" rid="hanspub.40890-ref30">30</xref>]。</p></sec><sec id="s8_2"><title>4.2. 黏膜相关恒定T细胞(MAIT)</title><p>黏膜相关恒定T细胞(MAIT)是近年来发现的固有样淋巴细胞，主要在粘膜组织、肝脏和血液中富集，可以分泌IL-22、IL-17及IFN-γ。有学者发现AS患者外周血中MAIT细胞的降低，而IL-17A<sup>+</sup>MAIT细胞比例升高，并在炎症关节中发现MAIT细胞富集，以IL-17表型为主。AS的MAIT细胞表面表达IL-7R受体，受到IL-7刺激后可以增强IL-17的分泌，而不依赖IL-23或者抗原刺激，表明在AS中MAIT可能在局部发挥不同的作用，也进一步确定了IL-17在发病中的关键作用，更提示存在不依赖传统IL-23/IL-17炎症通路的致病机制 [<xref ref-type="bibr" rid="hanspub.40890-ref31">31</xref>]。同样最近的一项研究也发现相较于健康人群，AS患者外周血中γδT细胞、MAIT细胞、IFN-γ<sup>+</sup>CD4<sup>+</sup>和CD8<sup>+</sup>T细胞的降低，与之前研究结果不同的是，发现了分泌IL-22的循环MAIT细胞在AS中增加 [<xref ref-type="bibr" rid="hanspub.40890-ref32">32</xref>]。这些结果表明IL-17的细胞来源并不局限于Th17 CD4<sup>+</sup>T细胞，IL-17A与IL-22也可能来源于固有样淋巴细胞。</p></sec><sec id="s8_3"><title>4.3. γδT细胞</title><p>γδT细胞是表面表达TCRγδ的T细胞，根据δ链的表达，可将其分为三个亚群：Vδ1T细胞，Vδ2T细胞和Vδ3T细胞，分别主要分布于胸腺和黏膜上皮组织、外周血和肝脏中，在人体固有免疫系统中发挥重要作用。有研究 [<xref ref-type="bibr" rid="hanspub.40890-ref33">33</xref>] 在IL-23诱导的小鼠中发现γδT细胞在肌腱端、主动脉根部及睫状体附近富集，并且是IL-17A的主要来源。最新的证据也表明在健康人类脊柱肌腱附着点发现了不依赖IL-23分泌IL-17的γδT细胞，其中存在2种亚型，Vδ1型的γδT细胞不同于Vδ2型，其表面几乎完全未检测到IL-23R转录 [<xref ref-type="bibr" rid="hanspub.40890-ref34">34</xref>]。也有研究发现了肌腱端中存在常规的CD4<sup>+</sup>和CD8<sup>+</sup>T细胞，其中CD8<sup>+</sup>T细胞表现出组织常驻的标志物，经过CD3/CD28刺激后可以分泌IL-17A及TNF，也提示IL-17的产生可能不依赖于IL-23 [<xref ref-type="bibr" rid="hanspub.40890-ref35">35</xref>]。TKY2负责编码JAK，通过1型IFN受体(IFNAR)、IL-10家族受体(IL-10R和IL-22R)和IL-12家族受体(IL-12R和IL-23R)介导信号传导。有研究通过TYK2抑制剂可以抑制SpA模型SKG小鼠的脊柱炎疾病进展，防止小鼠关节侵蚀破坏、骨髓水肿以及肌腱端炎性浸润，降低了Th17相关细胞因子(IL-17A、IL-22)水平；进一步通过IL-23微循环小鼠模型发现高表达的IL-23可以诱导局部γδT细胞的活化，TYK2在γδT细胞STAT3磷酸化中起着重要作用，并且发现IL-23诱导产生的IL-17A在很大程度上独立于TYK2/p-STAT3通路，而IL-22则依赖于TYK2/p-STAT3通路。表示这些γδT细胞在受到IL-23的刺激时产生IL-17和IL-22的通路是不同的 [<xref ref-type="bibr" rid="hanspub.40890-ref36">36</xref>]。这些研究表明IL-23/IL-17炎症通路在γδT细胞中似乎并不起主导作用。</p><p>这些固有性免疫细胞相较于适应性免疫细胞似乎在axSpA中发挥更多的作用，免疫细胞之间的相互作用导致这些细胞活化，肠–关节轴可能是这些细胞迁移至局部关节的方式，另外这些细胞存在不依赖常规的IL-23/IL-17炎症通路，IL-17的分泌不依赖IL-23的刺激，而IL-23的刺激也不以表达IL-17为主，这可能是解释药物实验结果的关键。</p></sec></sec><sec id="s9"><title>5. 炎症因子与异常新骨形成</title><p>在异常新骨形成的过程中间充质干细胞(MSCs)发挥着关键的作用。在一项基于三维仿生环境的研究中发现AS患者的间充质干细胞表现出更强的成骨分化能力，阻断Smad1/5/8和ERK信号通路则可以抑制成骨的分化，BMP2过表达是成骨分化及成骨信号通路增强的原因 [<xref ref-type="bibr" rid="hanspub.40890-ref37">37</xref>]。另外有研究同样发现组织非特异性碱性磷酸酶(TNAP)基因的表达升高与AS骨化关系密切，在MSCs中转录因子RARB的上调可以促进TNAP的表达，进一步研究发现HLA-B27可以介导AS-MSC的RARB/TNAP轴上调 [<xref ref-type="bibr" rid="hanspub.40890-ref38">38</xref>]。最新的研究则进一步发现多种炎性细胞因子，包括IL-17A，IL-22和IL-23均可以诱导成骨前体细胞的钙敏感受体(CaSR)的高表达，从而促进异常新骨形成 [<xref ref-type="bibr" rid="hanspub.40890-ref39">39</xref>]。因此炎症因子对于MSC起着重要的作用，但不同炎症因子对于MSC的作用不尽相同。</p><sec id="s9_1"><title>5.1. IL-17</title><p>有研究发现IL-17A可以诱导MSC向成骨细胞分化，当与成骨细胞接触时可以增强这一分化过程，促进炎性因子IL-6和IL-1β的分泌，并激活ERK1/2，AKT和STAT3信号通路，IL-6和IL-1β可以进一步激活骨形成的细胞间信号传导 [<xref ref-type="bibr" rid="hanspub.40890-ref40">40</xref>]。进一步研究发现IL-17A可以通过JAK2/STAT3信号传导调节成骨细胞的活性和分化。另一方面，IL-17也能导致骨质流失，研究发现AS患者的血清中IL-17A和miR-214的水平比健康对照组高得多，并且miR-214的水平与血清和滑膜中的IL-17A的水平呈正相关 [<xref ref-type="bibr" rid="hanspub.40890-ref41">41</xref>]。用IL-17A刺激成骨细胞和破骨细胞后，成骨细胞中RANKL和miR-214的表达增加，进一步促进破骨细胞中miR-214的表达和破骨细胞的活性，成骨细胞来源的miR-214可以转移至破骨细胞，然后调节其活性，导致骨质流失的发生 [<xref ref-type="bibr" rid="hanspub.40890-ref42">42</xref>]。这似乎可以解释临床上AS患者会同时出现骨质疏松与病理性成骨的症状 [<xref ref-type="bibr" rid="hanspub.40890-ref43">43</xref>]。</p></sec><sec id="s9_2"><title>5.2. IL-23</title><p>axSpA中尚缺乏IL-23与新骨形成的研究。IL-23通常由巨噬细胞、树突状细胞分泌，但在正常人体肌腱端中发现了可以分泌IL-23、TNF的CD14+骨髓细胞，且可能是局部产生IL-23的主要来源 [<xref ref-type="bibr" rid="hanspub.40890-ref44">44</xref>]。该细胞与血液中的骨髓细胞有相似的基因谱，因此尚不清楚这类细胞是否为组织常驻细胞，但也表明正常的肌腱端中含有能够产生局部细胞因子(包括TNF和IL-23)的骨髓细胞群。IL-23可以通过介导成骨和破骨活性来调节骨稳态和修复，IL-23缺乏会增加骨形成并增加骨量，并通过CD4<sup>+</sup>T细胞分泌IFN-γ和IL-17，虽然分泌的IL-17可以显著抑制RANKL诱导的破骨细胞生成。但在与IL-23共同作用下增强了破骨细胞分化，IL-23可以减少IL-17对破骨细胞形成的抑制作用 [<xref ref-type="bibr" rid="hanspub.40890-ref45">45</xref>]。进一步研究发现IFN-γ和IL-17间接抑制了MSC破骨的分化 [<xref ref-type="bibr" rid="hanspub.40890-ref46">46</xref>]，IL-17与IFN-γ协同作用诱导MSC凋亡，通过上调Fas和肿瘤坏死因子相关的凋亡诱导配体(TRAIL)的表达水平，以及通过激活MSC中的半胱天冬酶级联反应而发挥促凋亡作用。</p></sec><sec id="s9_3"><title>5.3. IL-22</title><p>有研究发现IL-22在炎性环境下参与MSC的增殖或迁移，可以促进MSC成骨分化，但在存在TNF或IFN-γ的条件下则抑制了该过程 [<xref ref-type="bibr" rid="hanspub.40890-ref47">47</xref>]。另外Sherlock在SpA小鼠中通过对分泌的IL-17和IL-22分别抑制后发现，IL-22可以促进STAT3磷酸化水平升高，更有效地诱导调控骨形成的基因，特别是编码Wnt家族成员、骨形态形成蛋白和碱性磷酸酶的基因，介导骨增生 [<xref ref-type="bibr" rid="hanspub.40890-ref24">24</xref>]。</p><p>总之，目前发现IL-17、IL-22可以单独诱导MSC成骨分化，IFN-γ可以阻断IL-22诱导的分化过程，IFN-γ与IL-17可以共同抑制破骨形成，而与IL-23的共同作用则可以诱导破骨分化。因此不同细胞因子的共同作用可能是axSpA局部新骨形成的重要因素之一。</p></sec></sec><sec id="s10"><title>6. 结语与展望</title><p>综上所述，近年临床药物试验的结果与之前研究结果相矛盾表明IL-23/IL-17炎症通路可能并不是axSpA发病的关键机制，但目前的证据尚不能认为IL-23/IL-17炎症通路解耦合。从目前发现的许多固有免疫细胞可以通过非IL-23依赖的方式分泌IL-17或者仅分泌IL-22或其他细胞因子来看，axSpA的致病机制并不是单纯的IL-23/IL-17炎症通路，更可能是多种免疫细胞之间或者与间质细胞之间的相互作用，以及多种细胞因子相互协同刺激导致局部炎症及骨化形成。目前来看，IL-17可能是最终效应的关键细胞因子之一，在炎症、成骨及骨质流失方面均发挥着重要作用；IL-23则可能与axSpA的发病初期有关，在局部可以诱导破骨细胞，但目前尚缺乏IL-23对于局部新骨形成的研究；IL-22在局部特定的条件下可以诱导成骨分化，也参与多种成骨通路介导骨形成，可能是局部新骨形成另一个重要原因，但目前IL-22在axSpA中的研究同样较少，与IL-23、IL-17等因子之间的协同作用仍是未知的。另外这些细胞因子可以对MSC产生迁移、分化及增殖等作用，这也可能是骨化形成的关键。因此研究免疫细胞之间或与局部环境下的其他细胞(如：MSC、骨髓细胞、肠上皮细胞)的相互作用以及细胞因子在其中的协同作用是探索axSpA发病机制可行的方向。本综述着眼于临床药物试验与基础研究的矛盾，结合最新的研究剖析可能的原因，进而为探索axSpA发病机制提供了新的方向。</p></sec><sec id="s11"><title>基金项目</title><p>本研究由上海市科委课题(18401901100)、上海市卫健委课题(202040396)资助。</p></sec><sec id="s12"><title>文章引用</title><p>刘 扬,朱 琦. IL-23/IL-17炎症通路在中轴型脊柱关节炎发病机制及治疗中的研究进展Research Progress of IL-23/IL-17 Axis in the Pathogenesis and Treatment of Axial Spondyloarthritis[J]. 临床医学进展, 2021, 11(03): 981-989. https://doi.org/10.12677/ACM.2021.113141</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40890-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bridgewood, C., Sharif, K., Sherlock, J., Watad, A. and McGonagle, D. (2020) Interleukin-23 Pathway at the Enthesis: The Emerging Story of Enthesitis in Spondyloarthropathy. Immunological Reviews, 294, 27-47. 
&lt;br&gt;https://doi.org/10.1111/imr.12840</mixed-citation></ref><ref id="hanspub.40890-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wellcome Trust Case Control Consortium and the Australo-Anglo-American Spondylitis Consortium (TASC) (2007) Association Scan of 14,500 Nonsynonymous SNPs in Four Diseases Identifies Autoimmunity Variants. Nature Genetics, 39, 1329-1337. &lt;br&gt;https://doi.org/10.1038/ng.2007.17</mixed-citation></ref><ref id="hanspub.40890-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Uddin, M., Codner, D., Hasan, S.M., Scherer, S.W., O’Rielly, D.D and Rahman, P. (2015) Integrated Genomics Identifies Convergence of Ankylosing Spondylitis with Global Immune Mediated Disease Pathways. Scientific Reports, 5, Article No. 10314. &lt;br&gt;https://doi.org/10.1038/srep10314</mixed-citation></ref><ref id="hanspub.40890-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Danoy, P., Pryce, K., Hadler, J., Bradbury, L.A., Farrar, C., Pointon, J., et al. (2010) Association of Variants at 1q32 and STAT3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn’s Disease. PLoS Genetics, 6, e1001195.  
&lt;br&gt;https://doi.org/10.1371/journal.pgen.1001195</mixed-citation></ref><ref id="hanspub.40890-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Brown, M.A., Kenna, T. and Wordsworth, B.P. (2016) Genetics of Ankylosing Spondylitis—Insights into Pathogenesis. Nature Reviews Rheumatology, 12, 81-91. &lt;br&gt;https://doi.org/10.1038/nrrheum.2015.133</mixed-citation></ref><ref id="hanspub.40890-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">International Genetics of Ankylosing Spondylitis Consortium (2013) Identification of Multiple Risk Variants for Ankylosing Spondylitis through High-Density Genotyping of Immune-Related Loci. Nature Genetics, 45, 730-738. 
&lt;br&gt;https://doi.org/10.1038/ng.2667</mixed-citation></ref><ref id="hanspub.40890-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ward, M.M., Deodhar, A., Gensler, L.S., Dubreuil, M., Yu, D., Khan, M.A., et al. (2019) 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis &amp; Rheumatology, 71, 1599-1613. &lt;br&gt;https://doi.org/10.1002/art.41042</mixed-citation></ref><ref id="hanspub.40890-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., et al. (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. New England Journal of Medicine, 373, 2534-2548. 
&lt;br&gt;https://doi.org/10.1056/NEJMoa1505066</mixed-citation></ref><ref id="hanspub.40890-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Braun, J., Baraliakos, X., Deodhar, A., Baeten, D., Sieper, J., Emery, P., et al. (2017) Effect of Secukinumab on Clinical and Radiographic outcomes in Ankylosing Spondylitis: 2-Year Results from the Randomised Phase III MEASURE 1 Study. Annals of the Rheumatic Diseases, 76, 1070-1077. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2016-209730</mixed-citation></ref><ref id="hanspub.40890-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Baraliakos, X., Kivitz, A.J., Deodhar, A.A., Braun, J., Wei, J.C., Maria Delicha, E., et al. (2018) Long-Term Effects of Interleukin-17A Inhibition with Secukinumab in Active Ankylosing Spondylitis: 3-Year Efficacy and Safety Results from an Extension of the Phase 3 MEASURE 1 Trial. Clinical and Experimental Rheumatology, 36, 50-55.</mixed-citation></ref><ref id="hanspub.40890-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Marzo-Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Martin, R., et al. (2017) Secukinumab and Sustained Improvement in Signs and Symptoms of Patients with Active Ankylosing Spondylitis through Two Years: Results from a Phase III Study. Arthritis Care &amp; Research, 69, 1020-1029. &lt;br&gt;https://doi.org/10.1002/acr.23233</mixed-citation></ref><ref id="hanspub.40890-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Marzo-Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Delicha, E.-M., et al. (2017) Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with High Retention Rate: 3-Year Results from the Phase III Trial, MEASURE 2. RMD Open, 3, e000592.  
&lt;br&gt;https://doi.org/10.1136/rmdopen-2017-000592</mixed-citation></ref><ref id="hanspub.40890-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">van der Heijde, D., Cheng-Chung, W.J., Dougados, M., Mease, P., Maksymowych, W.P., Van den Bosch, F., et al. (2018) Ixekizumab, an Interleukin-17A Antagonist in the Treatment of Ankylosing Spondylitis or Radiographic Axial Spondyloarthritis in Patients Previously Untreated with Biological Disease-Modifying Anti-Rheumatic Drugs (COAST-V): 16 Week Results of a Phase 3 Randomised, Double-Blind, Active-Controlled and Placebo-Controlled Trial. Lancet, 392, 2441-2451. &lt;br&gt;https://doi.org/10.1016/S0140-6736(18)31946-9</mixed-citation></ref><ref id="hanspub.40890-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Deodhar, A., Poddubnyy, D., Pacheco-Tena, C., Salvarani, C., Lespessailles, E., Rahman, P., et al. (2019) Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis &amp; Rheumatology, 71, 599-611. &lt;br&gt;https://doi.org/10.1002/art.40753</mixed-citation></ref><ref id="hanspub.40890-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Mease, P., Walsh, J.A., Baraliakos, X., Inman, R., de Vlam, K., Wei, J.C.-C., et al. (2019) Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatology and Therapy, 6, 435-450. &lt;br&gt;https://doi.org/10.1007/s40744-019-0165-3</mixed-citation></ref><ref id="hanspub.40890-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Dougados, M., Wei, J.C., Landewe, R., Sieper, J., Baraliakos, X., Van den Bosch, F., et al. (2020) Efficacy and Safety of Ixekizumab through 52 Weeks in Two Phase 3, Randomised, Controlled Clinical Trials in Patients with Active Radiographic Axial Spondyloarthritis (COAST-V and COAST-W). Annals of the Rheumatic Diseases, 79, 176-185. 
&lt;br&gt;https://doi.org/10.1136/annrheumdis-2019-216118</mixed-citation></ref><ref id="hanspub.40890-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Deodhar, A., van der Heijde, D., Gensler, L.S., Kim, T.H., Maksymowych, W.P., Østergaard, M., et al. (2020) Ixekizumab for Patients with Non-Radiographic Axial Spondyloarthritis (COAST-X): A Randomised, Placebo-Controlled Trial. Lancet, 395, 53-64. &lt;br&gt;https://doi.org/10.1016/S0140-6736(19)32971-X</mixed-citation></ref><ref id="hanspub.40890-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">van der Heijde, D., Gensler, L.S., Deodhar, A., Baraliakos, X., Poddubnyy, D., Kivitz, A., et al. (2020) Dual Neutralisation of Interleukin-17A and Interleukin-17F with bimekizumab in Patients with Active Ankylosing Spondylitis: Results from a 48-Week Phase IIb, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study. Annals of the Rheumatic Diseases, 79, 595-604. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2020-216980</mixed-citation></ref><ref id="hanspub.40890-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Deodhar, A., Gensler, L.S., Sieper, J., Clark, M., Calderon, C., Wang, Y., et al. (2019) Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis &amp; Rheumatology, 71, 258-270. &lt;br&gt;https://doi.org/10.1002/art.40728</mixed-citation></ref><ref id="hanspub.40890-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Baeten, D., Ostergaard, M., Wei, J.C., Sieper, J., Järvinen, P., Tam, L.-S., et al. (2018) Risankizumab, an IL-23 Inhibitor, for Ankylosing Spondylitis: Results of a Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept, Dose-Finding Phase 2 Study. Annals of the Rheumatic Diseases, 77, 1295-1302.  
&lt;br&gt;https://doi.org/10.1136/annrheumdis-2018-213328</mixed-citation></ref><ref id="hanspub.40890-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">van Tok, M.N., Na, S., Lao, C.R., Alvi, M., Pots, D., van de Sande, M.G.H., et al. (2018) The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling. Frontiers in Immunology, 9, 1550. &lt;br&gt;https://doi.org/10.3389/fimmu.2018.01550</mixed-citation></ref><ref id="hanspub.40890-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">van Tok, M.N., van Duivenvoorde, L.M., Kramer, I., Ingold, P., Pfister, S., Roth, L., et al. (2019) Interleukin-17A Inhibition Diminishes Inflammation and New Bone Formation in Experimental Spondyloarthritis. Arthritis &amp; Rheumatology, 71, 612-625. &lt;br&gt;https://doi.org/10.1002/art.40770</mixed-citation></ref><ref id="hanspub.40890-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sieper, J., Poddubnyy, D. and Miossec, P. (2019) The IL-23-IL-17 Pathway as a Therapeutic Target in Axial Spondyloarthritis. Nature Reviews Rheumatology, 15, 747-757. &lt;br&gt;https://doi.org/10.1038/s41584-019-0294-7</mixed-citation></ref><ref id="hanspub.40890-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sherlock, J.P., Joyce-Shaikh, B., Turner, S.P., Chao, C.C., Sathe, M., Grein, J., et al. (2012) IL-23 Induces Spondyloarthropathy by Acting on ROR-Gammat+ CD3+CD4-CD8− Entheseal Resident T Cells. Nature Medicine, 18, 1069-1076.  
&lt;br&gt;https://doi.org/10.1038/nm.2817</mixed-citation></ref><ref id="hanspub.40890-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ciccia, F., Guggino, G., Rizzo, A., Saieva, L., Peralta, S., Giardina, A.R., et al. (2015) Type 3 Innate Lymphoid Cells Producing IL-17 and IL-22 Are Expanded in the Gut, in the Peripheral Blood, Synovial Fluid and Bone Marrow of Patients with Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 74, 1739-1747. 
&lt;br&gt;https://doi.org/10.1136/annrheumdis-2014-206323</mixed-citation></ref><ref id="hanspub.40890-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Crellin, N.K., Trifari, S., Kaplan, C.D., Cupedo, T. and Spits, H. (2010) Human NKp44+IL-22+ Cells and LTi-Like Cells Constitute a Stable RORC+ Lineage Distinct from Conventional Natural Killer Cells. Journal of Experimental Medicine, 207, 281-290. &lt;br&gt;https://doi.org/10.1084/jem.20091509</mixed-citation></ref><ref id="hanspub.40890-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Blijdorp, I., Menegatti, S., van Mens, L., van de Sande, M., Chen, S., Hreggvidsdottir, H.S., et al. (2019) Expansion of Interleukin-22- and Granulocyte-Macrophage Colony-Stimulating Factor-Expressing, but Not Interleukin-17A-Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients with Spondyloarthritis. Arthritis &amp; Rheumatology, 71, 392-402. &lt;br&gt;https://doi.org/10.1002/art.40736</mixed-citation></ref><ref id="hanspub.40890-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Al-Mossawi, M.H., Chen, L., Fang, H., Ridley, A., de Wit, J., Yager, N., et al. (2017) Unique Transcriptome Signatures and GM-CSF Expression in Lymphocytes from Patients with Spondyloarthritis. Nature Communications, 8, Article No. 1510. &lt;br&gt;https://doi.org/10.1038/s41467-017-01771-2</mixed-citation></ref><ref id="hanspub.40890-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Shi, H., Chen, L., Ridley, A., Zaarour, N., Brough, I., Caucci, C., et al. (2020) GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis. Frontiers in Immunology, 11, 1520. 
&lt;br&gt;https://doi.org/10.3389/fimmu.2020.01520</mixed-citation></ref><ref id="hanspub.40890-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Ciccia, F., Guggino, G., Zeng, M., Thomas, R., Ranganathan, V., Rahman, A., et al. (2018) Proinflammatory CX3CR1+CD59+Tumor Necrosis Factor-Like Molecule 1A+Interleukin-23+ Monocytes Are Expanded in Patients with Ankylosing Spondylitis and Modulate Innate Lymphoid Cell 3 Immune Functions. Arthritis &amp; Rheumatology, 70, 2003-2013. &lt;br&gt;https://doi.org/10.1002/art.40582</mixed-citation></ref><ref id="hanspub.40890-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Gracey, E., Qaiyum, Z., Almaghlouth, I., Lawson, D., Karki, S., Avvaru, N., et al. (2016) IL-7 Primes IL-17 in Mucosal-Associated Invariant T (MAIT) Cells, Which Contribute to the Th17-Axis in Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 75, 2124-2132. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2015-208902</mixed-citation></ref><ref id="hanspub.40890-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Toussirot, E., Laheurte, C., Gaugler, B., Gabriel, D. and Saas, P. (2018) Increased IL-22- and IL-17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients with Ankylosing Spondylitis. Frontiers in Immunology, 9, 1610. &lt;br&gt;https://doi.org/10.3389/fimmu.2018.01610</mixed-citation></ref><ref id="hanspub.40890-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Reinhardt, A., Yevsa, T., Worbs, T., Lienenklaus, S., Sandrock, I., Oberdörfer, L., et al. (2016) Interleukin-23-Dependent Gamma/Delta T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice. Arthritis &amp; Rheumatology, 68, 2476-2486. &lt;br&gt;https://doi.org/10.1002/art.39732</mixed-citation></ref><ref id="hanspub.40890-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Cuthbert, R.J., Watad, A., Fragkakis, E.M., Dunsmuir, R., Loughenbury, P., Khan, A., et al. (2019) Evidence That Tissue Resident Human Enthesis Gammadelta T-Cells Can Produce IL-17A Independently of IL-23R Transcript Expression. Annals of the Rheumatic Diseases, 78, 1559-1565. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2019-215210</mixed-citation></ref><ref id="hanspub.40890-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Watad, A., Rowe, H., Russell, T., Zhou, Q., Anderson, L.K., Khan, A., et al. (2020) Normal Human Enthesis Harbours Conventional CD4+ and CD8+ T Cells with Regulatory Features and Inducible IL-17A and TNF Expression. Annals of the Rheumatic Diseases, 79, 1044-1054. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2020-217309</mixed-citation></ref><ref id="hanspub.40890-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Gracey, E., Hromadova, D., Lim, M., Qaiyum, Z., Zeng, M., Yao, Y.C., et al. (2020) TYK2 Inhibition Reduces Type 3 Immunity and Modifies Disease Progression in Murine Spondyloarthritis. Journal of Clinical Investigation, 130, 1863-1878. &lt;br&gt;https://doi.org/10.1172/JCI126567</mixed-citation></ref><ref id="hanspub.40890-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, G., Xie, Z., Wang, P., Li, J., Li, M., Cen, S., et al. (2019) Enhanced Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis: A Study Based on a Three-Dimensional Biomimetic Environment. Cell Death &amp; Disease, 10, Article No. 350. &lt;br&gt;https://doi.org/10.1038/s41419-019-1586-1</mixed-citation></ref><ref id="hanspub.40890-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Liu, C.H., Raj, S., Chen, C.H., Hung, K.H., Chou, C.-T., Chen, I.-H., et al. (2019) HLA-B27-Mediated Activation of TNAP Phosphatase Promotes Pathogenic Syndesmophyte Formation in Ankylosing Spondylitis. Journal of Clinical Investigation, 129, 5357-5373. &lt;br&gt;https://doi.org/10.1172/JCI125212</mixed-citation></ref><ref id="hanspub.40890-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Chen, S., Hu, Z., Chen, D., Wang, J., Li, Z., et al. (2020) Aberrant Upregulation of CaSR Promotes Pathological New Bone Formation in Ankylosing Spondylitis. EMBO Molecular Medicine, 12, e12109. 
&lt;br&gt;https://doi.org/10.15252/emmm.202012109</mixed-citation></ref><ref id="hanspub.40890-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Liao, C., Zhang, C., Jin, L. and Yang, Y. (2020) IL-17 Alters the Mesenchymal Stem Cell Niche towards Osteogenesis in Cooperation with Osteocytes. Journal of Cellular Physiology, 235, 4466-4480. 
&lt;br&gt;https://doi.org/10.1002/jcp.29323</mixed-citation></ref><ref id="hanspub.40890-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Jo, S., Wang, S.E., Lee, Y.L., Kang, S., Lee, B., Han, J., et al. (2018) IL-17A Induces Osteoblast Differentiation by Activating JAK2/STAT3 in Ankylosing Spondylitis. Arthritis Research &amp; Therapy, 20, Article No. 115. 
&lt;br&gt;https://doi.org/10.1186/s13075-018-1582-3</mixed-citation></ref><ref id="hanspub.40890-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Z., Huang, F., Luo, G., Wang, Y., Du, R., Sun, W., et al. (2020) miR-214 Stimulated by IL-17A Regulates Bone Loss in Patients with Ankylosing Spondylitis. Rheumatology, 59, 1159-1169.  
&lt;br&gt;https://doi.org/10.1093/rheumatology/kez594</mixed-citation></ref><ref id="hanspub.40890-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Klingberg, E., Lorentzon, M., Gothlin, J., Mellstrom, D., Geijer, M., Ohlsson, C., et al. (2013) Bone Microarchitecture in Ankylosing Spondylitis and the Association with Bone Mineral Density, Fractures, and Syndesmophytes. Arthritis Research &amp; Therapy, 15, Article No. R179. &lt;br&gt;https://doi.org/10.1186/ar4368</mixed-citation></ref><ref id="hanspub.40890-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Bridgewood, C., Watad, A., Russell, T., Palmer, T.M., Marzo-Ortega, H., Khan, A., et al. (2019) Identification of Myeloid Cells in the Human Enthesis as the Main Source of Local IL-23 Production. Annals of the Rheumatic Diseases, 78, 929-933. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2018-214944</mixed-citation></ref><ref id="hanspub.40890-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J., Li, J., Hu, Y., Dai, K., Gan, Y., Zhao, J., et al. (2020) IL-23, but Not IL-12, Plays a Critical Role in Inflammation-Mediated Bone Disorders. Theranostics, 10, 3925-3938. &lt;br&gt;https://doi.org/10.7150/thno.41378</mixed-citation></ref><ref id="hanspub.40890-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J., Wang, Y., Li, J., Zhang, X., Geng, Y., Huang, Y., et al. (2016) IL-12p40 Impairs Mesenchymal Stem Cell-Mediated Bone Regeneration via CD4+ T Cells. Cell Death &amp; Differentiation, 23, 1941-1951. 
&lt;br&gt;https://doi.org/10.1038/cdd.2016.72</mixed-citation></ref><ref id="hanspub.40890-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">El-Zayadi, A.A., Jones, E.A., Churchman, S. M., Baboolal, T.G., Cuthbert, R.J., El-Jawhari, J.J., et al. (2017) Interleukin-22 Drives the Proliferation, Migration and Osteogenic Differentiation of Mesenchymal Stem Cells: A Novel Cytokine That Could Contribute to New Bone Formation in Spondyloarthropathies. Rheumatology, 56, 488-493. 
&lt;br&gt;https://doi.org/10.1093/rheumatology/kew384</mixed-citation></ref></ref-list></back></article>